---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-068757"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-03-08T23:59:59+00:00"
generated_at: "2026-06-27T00:49:21.911624+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics reports Q4 2021 net loss $19.3M; first patient dosed in MGTA-117 trial

## Summary
- Cash, cash equivalents and marketable securities at Dec 31, 2021: $176.9M, expected to fund operations into Q4 2023.
- First patient dosed and completed initial safety assessment in Phase 1/2 trial of MGTA-117 targeted conditioning; data expected in 2022.
- IND-enabling studies initiated for CD45-ADC; dose-ranging toxicology results anticipated in H2 2022.
- MGTA-145 stem cell mobilization program advancing in sickle cell disease; data expected in H2 2022.
- Net loss of $19.3M for Q4 2021 vs. $18.2M in Q4 2020; R&D expenses increased to $13.1M.

## SEC filing metadata
- accession: 0001193125-22-068757
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-03-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522068757/0001193125-22-068757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522068757/d682941d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-068757
- JSON: https://secwatch.observer/filing/0001193125-22-068757.json
- Plain text: https://secwatch.observer/filing/0001193125-22-068757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.